Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Date of Graduation
12-17-2021
Course Instructor
Abby Massey
Abstract
As of October 2020, there are no commonly accepted or proven effective treatments for coronavirus disease 2019 (COVID-19). Hydroxychloroquine (HCQ) is an established anti-malarial drug with demonstrated action against SARS-CoV-2 (the virus that causes COVID-19) in-vitro and early observational studies and anecdotal evidence supported its use in treatment of COVID-19. In this review, three of largest and most statistically powerful studies to date (two cohort studies and one randomized controlled trial [RCT]) are synthesized for the purpose of determining whether HCQ is effective in reducing mortality in patients hospitalized with COVID-19. All three studies found no statistically significant difference in mortality between patients treated with HCQ and patients in a control group (receiving only standard care). Although evidence on the use of HCQ to treat COVID-19 has been conflicting and controversial, this review finds no evidence to support its continued use.
Recommended Citation
Suresh M, Abraham J. The Effect of Hydroxychloroquine on Mortality in Hospitalized COVID-19 Patients
